Establishment and Effectiveness of Drug Treatment Pathway for the Initial Treatment of Diffuse Large B-Cell Lymphoma Under the DRG Payment System
10.3870/j.issn.1004-0781.2025.07.023
- VernacularTitle:初治弥漫大B细胞淋巴瘤药物治疗路径的制订与应用成效
- Author:
Zheng ZENG
1
;
Dawei WAN
;
Wei CHEN
;
Leyong FAN
;
Tongtong CHEN
;
Aiping DING
;
Shengguang YUAN
Author Information
1. 桂林医科大学第一附属医院 药学部,桂林 541000
- Publication Type:Journal Article
- Keywords:
Drug treatment pathway;
Primary diffuse large B-cell lymphoma;
Diagnosis related groups
- From:
Herald of Medicine
2025;44(7):1158-1164
- CountryChina
- Language:Chinese
-
Abstract:
Objective To develop and implement a drug treatment pathway for the initial treatment of diffuse large B-cell lymphoma(DLBCL)and to provide a foundation for refined medication use and cost control management under the Diagnosis Related Groups(DRG)payment system.Methods Clinical pharmacists collaborated to develop a drug treatment pathway for the initial treatment of DLBCL,utilizing evidence-based medicine and evidence-based pharmacy principles.The PDCA(Plan-Do-Check-Act)cycle method was employed for administrative intervention.The hematology department served as a pilot unit to assess the impact on economic indicators,including inpatient costs,drug expenses,and DRG payment balance,as well as treatment efficacy and the incidence of adverse reactions.Results Compared to the control group,the RG13 intervention group exhibited a significant reduction in average total hospitalization costs and drug expenses,along with a decreased DRG payment balance deficits.All differences were statistically significant(P＜0.05).Conclusion The development and implementation of a drug treatment pathway for the initial treatment of DLBCL can effectively reduce treatment costs,prevent DRG overspending,and alleviate the economic burden on patients,while ensuring the safety and effectiveness of the treatment.
